DDInter630 DDInter875
Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Elotuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Paclitaxel
Elotuzumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Candida albicans
Elotuzumab {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Elotuzumab {u} may lead to a major life threatening interaction when taken with {v} Samarium (153Sm) lexidronam
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Elotuzumab may lead to a major life threatening interaction when taken with Fingolimod
Elotuzumab may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam